Core Insights - V2X has appointed Stan Budraitis as Vice President of Business Development for Army Aviation Programs, bringing 35 years of experience as a U.S. Army Aviator [1][2] - Budraitis previously served as Deputy Commanding General at the U.S. Army Aviation Center of Excellence and has extensive leadership experience in Army aviation [2][3] - His operational expertise and strategic insight are expected to enhance V2X's support for Army aviation customers and expand mission-critical capabilities [3] Company Overview - V2X specializes in innovative solutions that integrate physical and digital environments, focusing on enhancing readiness, optimizing resource management, and boosting security [4] - The company operates across national security, defense, civilian, and international markets, employing approximately 16,000 professionals globally [4] - V2X leverages AI and machine learning to address complex challenges across various operational domains [4]

Core Viewpoint - Predictive Oncology reported a loss from continuing operations of approximately $2.0 million for Q2 2025, while focusing on advancing its AI-driven drug discovery and expanding its ChemoFx assay in the U.S. and Europe [1][3]. Financial Summary - The company concluded Q2 2025 with cash and cash equivalents of $506,078, down from $611,822 as of December 31, 2024 [4]. - Revenue for Q2 2025 was $2,682, a significant decrease from $67,255 in Q2 2024, primarily due to reduced sales of tumor-specific 3D models and kits [10]. - General and administrative expenses increased to $1,875,655 in Q2 2025 from $1,825,174 in Q2 2024, mainly due to higher legal fees [10]. - The company raised approximately $586,000 in gross proceeds during the quarter through private placements and its At-the-Market facility [6]. Operational Highlights - The company is preparing for an aggressive market expansion of its ChemoFx assay in the U.S. and a de novo launch in Europe, both expected in Q4 2025 [5]. - ChemoFx helps oncologists make better treatment decisions by testing multiple chemotherapies on patients' cancer cells before treatment selection [5]. - Predictive Oncology has developed two unique 3D liver toxicity models for Labcorp, which can evaluate drug metabolism and liver toxicity [5]. - The company identified three promising candidates for repurposing from abandoned drugs, specifically Afuresertib, Alisertib, and Entinosta, for colon and breast tumor indications [5]. Capital and Investment - A standby equity purchase agreement for up to $10 million was announced with YA II PN, LTD, managed by Yorkville Advisors Global, LP, providing a flexible source of capital for advancing initiatives [5].

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $15.3 million, up from $8 million in Q2 2024, primarily due to variability in Pharma Biocatalysis customers' manufacturing schedules and clinical trial progression [14][15] - Product gross margin increased to 72% in Q2 2025 from 45% in Q2 2024, attributed to shifts in sales to more profitable products [15][17] - The net loss for Q2 2025 was $13.3 million, compared to $22.8 million in Q2 2024, indicating improved financial performance [17] Business Line Data and Key Metrics Changes - The Pharma Biocatalysis business saw increased orders for enzymes supporting late-phase and commercialized APIs, contributing to strong Q2 revenue [6][14] - The Ecosynthesis platform is experiencing strong customer engagement, with over 30 ongoing customer engagements, indicating growing demand [5][21] Market Data and Key Metrics Changes - The demand for the Ecosynthesis platform is expected to exceed supply, prompting the company to explore options to expand capacity [5][12] - The ligation process is becoming the new standard in siRNA manufacturing, with the company focusing on acquiring new ligase customers [9][10] Company Strategy and Development Direction - The company aims to achieve cash flow breakeven by 2026 while exploring ways to maximize stockholder value through the Ecosynthesis platform [4][5] - A strategy is in place to secure early-phase products on the ECO platform, which could lead to significant returns as these products mature into commercial drugs [5][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the trajectory towards profitability and highlighted the importance of managing expenses while capitalizing on the strong cash position [17] - The company anticipates continued revenue lumpiness in the near term due to the unpredictability of the heritage business, but expects growth from the Ecosynthesis platform in the coming years [15][30] Other Important Information - The company ended the quarter with $66.3 million in cash and equivalents, sufficient to fund operations through 2027 [18] - Management is focused on establishing a GMP facility to improve the scale-up process and service small to medium-sized drug innovators [12][34] Q&A Session Summary Question: Can you provide an update on the pipeline and customer discussions? - The company has over 30 discussions ongoing, potentially growing into the 40s, with a mix of CDMOs and biopharma companies [21][22] Question: What is the status of process development projects in the Eco Innovation Lab? - The company is excited about recruiting early-phase projects and is considering setting up a second Eco Lab to increase capacity [27][28] Question: How does the company plan to expand bandwidth for the ECO platform? - The focus is on filling existing capacity and exploring partnerships while ensuring a credible path to GMP material [33][35] Question: What is the company's IP position around Ecosynthesis? - The company has a strong IP portfolio and emphasizes the importance of trade secrets and know-how in maintaining a competitive edge [37][38] Question: How should investors think about revenue collection pace? - The company aims to lock in a large number of early-stage projects, which could lead to significant future revenues as these assets mature [42][46] Question: What are the options for funding scaling to GMP? - The company is not considering selling its biocatalysis business, as it is profitable and reduces cash needs, while also planning incremental scaling [68][69]

As filed with the Securities and Exchange Commission on August 13, 2025 Registration Number 333-288747 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RedCloud Holdings plc (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) England and Wales 5990 Not Applicable (I.R.S. Employer I ...

Core Insights - Tevogen Bio Holdings Inc. is expanding its collaboration with Microsoft and Databricks to develop the beta version of its PredicTcell model, focusing on oncology [1][7] - The initiative aims to enhance the accuracy of the PredicTcell model by curating a dataset that combines oncology and virology data [2][7] - The development is supported by a recently published international patent application outlining novel machine learning systems for predicting immunologically active peptides, crucial for targeted therapies [3] Company Developments - Tevogen.AI is leveraging the Databricks Data Intelligence Platform to improve its foundational AI model, which is particularly impactful in drug discovery for oncology [2][4] - The company plans to explore external market opportunities as a potential revenue source while enhancing analytics and visualization tools for its internal R&D teams [7] - The collaboration with Microsoft and Databricks has been highlighted as a significant advantage in building the alpha version of the AI model [4]

RT Avi Chawla (@_avichawla)Generative vs. discriminative models in ML:(a popular ML interview question) https://t.co/bOWdx8CywA ...

Core Insights - NextNRG, Inc. has appointed Michael Weisz to its Strategic Advisory Board, bringing extensive experience in scaling investment platforms and executing strategic M&A [1][3][4] - Weisz previously founded Yieldstreet, which deployed over $6 billion across various asset classes and became the largest direct-to-consumer alternative investment platform in the U.S. [2][5] - NextNRG aims to leverage AI and machine learning to transform energy production and management, focusing on smart microgrids and wireless EV charging solutions [7][8][10] Company Overview - NextNRG is focused on AI-driven energy innovation, implementing solutions like the Next Utility Operating System® and smart microgrids to enhance energy efficiency and reduce costs [7][8] - The company is expanding its operations in multiple energy sectors and geographic markets, including the acquisition of Yoshi Mobility's fuel division and Shell Oil's trucks [10] - NextNRG's technology aims to support the transition to electric vehicles (EV) and improve energy accessibility while contributing to decarbonization efforts [9][10] Leadership and Strategy - Michael Weisz's appointment is expected to strengthen NextNRG's go-to-market strategy and growth initiatives, leveraging his expertise in capital markets and strategic partnerships [3][4] - The company is positioned at the intersection of the AI revolution and the global energy transition, aiming to create significant value through disciplined execution and intelligent capital deployment [3][10] - NextNRG's Strategic Advisory Board is chaired by Gary M. Goldfarb, enhancing the company's strategic direction as it continues to grow [3]

Core Insights - The Defiance Quantum ETF (NASDAQ: QTUM) is designed to provide investors exposure to companies involved in quantum computing and machine learning with a low expense ratio of 40 basis points [1] Group 1: Investment Strategy - QTUM offers an indexed investment strategy focusing on quantum computing and machine learning sectors [1] Group 2: Analyst Background - Michael Del Monte, a buy-side equity analyst with over 5 years of experience, emphasizes a holistic approach to investment recommendations, considering the entire investment ecosystem rather than evaluating companies in isolation [1]

Generative vs. discriminative models in ML:(a popular ML interview question) https://t.co/bOWdx8CywA ...

Financial Data and Key Metrics Changes - Revenue for Q2 2025 was $31.7 million, marking an 8% decline year-over-year, primarily due to reduced dispatch volume from a top customer and the autonomous business [21][22] - Gross profit increased to $7.9 million, with a gross margin of 25%, up from 21.2% in the same period last year, driven by margin improvement initiatives [22] - Non-GAAP operating loss was approximately $199,000, a 97% improvement compared to $6.2 million in the prior year [27] Business Line Data and Key Metrics Changes - The company secured two renewals for 2025, contributing to revenue stability, with 40% of the renewals completed so far [38] - The focus on the insurance market has led to a new contract with a premium insurance provider and ongoing negotiations with two additional providers [13][41] Market Data and Key Metrics Changes - The company is targeting mid-tier insurance providers, which are currently underserved, and has initiated a sales plan to reach these markets [12][41] - The AI-powered market analyzer, Spark, has been launched to enhance service performance across urban markets, showing significant improvements in wait times [15][16] Company Strategy and Development Direction - The company aims to return to growth by expanding existing B2B incident business and developing new customer partnerships [18] - Continued investment in AI and machine learning is seen as critical for maintaining competitive advantage and improving customer satisfaction [14][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving non-GAAP operating breakeven in Q3 2025, with expectations for revenue growth to begin in late Q3 or early Q4 [29][31] - The company anticipates a flattening of seasonal revenue drops due to AI and machine learning initiatives [32] Other Important Information - As of June 30, 2025, the company had cash and cash equivalents of $4.8 million and a principal debt balance of $55.3 million [27][28] - The company has entered into a sales agreement to sell shares through an ATM program, although no shares have been sold yet [28] Q&A Session Summary Question: When should revenue growth from the premium insurance provider be expected? - Management expects to see revenue growth from the premium insurance provider by the end of Q3 or beginning of Q4, targeting 20% to 30% growth post-autonomous business [31] Question: Will the new revenue overwhelm typical seasonality in Q4? - Management noted that the seasonality curve is flattening due to AI work, suggesting continued revenue growth despite typical seasonal drops [32] Question: How much of the revenue do the renewals account for? - Renewals completed so far account for 40% of the revenue expected for the year [38] Question: What is the status of the sales cycle for new contracts? - The sales cycle is consistent with expectations, with larger companies moving slower and smaller companies moving faster [44] Question: When will nonrecurring transaction costs head towards zero? - Management indicated that the specific costs related to the autonomous business are expected to cease, with minimal ongoing costs anticipated [47]